H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Minerva to $5 from $7 and keeps a Neutral rating on the shares. The pathway of roluperidone is still unclear, the analyst tells investors in a research note. The firm firm cites ongoing questions on the path forward and the need for additional funding for the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NERV: